Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GAA | P10253 | 3/20 | 0.41 |
| ▸ | MGAM | O43451 | 1/20 | 0.41 |
| ▸ | SI | P14410 | 1/20 | 0.41 |
| ▸ | MGAM2 | Q2M2H8 | 1/20 | 0.41 |
| ▸ | NPSR1 | Q6W5P4 | 3/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.39 |
| ▸ | TRPA1 | O75762 | 1/20 | 0.39 |
| ▸ | TSHR | P16473 | 1/20 | 0.35 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.35 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.34 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.34 |
| ▸ | NLRP3 | Q96P20 | 1/20 | 0.34 |
| ▸ | HSD17B10 | Q99714 | 3/20 | 0.34 |
| ▸ | TP53 | P04637 | 2/20 | 0.34 |
| ▸ | HPGD | P15428 | 2/20 | 0.34 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.34 |
| ▸ | TLR9 | Q9NR96 | 2/20 | 0.34 |
| ▸ | MAPT | P10636 | 1/20 | 0.34 |
| ▸ | RAB9A | P51151 | 1/20 | 0.34 |
| ▸ | BCL2A1 | Q16548 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17777235 | 0.82 | NAAA (0.42) | NPSR1ALDH1A1TSHRHPGD | |
| SCHEMBL13537808 | 0.82 | GAA (0.34) | GAAMGAMSIMGAM2NPSR1 | |
| SCHEMBL1509202 | 0.80 | TSHR (0.37) | GAAMGAMSIMGAM2NPSR1 | |
| SCHEMBL8374416 | 0.79 | CA2 (0.34) | ALDH1A1 | |
| Hydrogen Sulfide SCHEMBL8355994 | 0.78 | TSHR (0.36) | GAAMGAMSIMGAM2ALDH1A1 | |
| SCHEMBL27800814 | 0.77 | PSEN1 (0.36) | — | |
| SCHEMBL27924479 | 0.77 | CA12 (0.33) | ALDH1A1TSHRPOLB | |
| SCHEMBL166799 | 0.76 | CYP1A2 (0.36) | GAAMGAMSIMGAM2NPSR1 | |
| SCHEMBL4880094 | 0.76 | DGKA (0.43) | GAAALDH1A1TSHRCYP1A2KMT2A | |
| SCHEMBL17469816 | 0.75 | GAA (0.48) | GAAMGAMSIMGAM2NPSR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 54 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250100999-A1 | METHODS AND INTERMEDIATES FOR PREPARING THERAPEUTIC COMPOUNDS | GILEAD SCIENCES, INC. | 2025-03-27 | — | — | US | disclosed |
| US-12122765-B2 | Methods and intermediates for preparing therapeutic compounds | GILEAD SCIENCES, INC. (US) | 2024-10-22 | — | — | US | disclosed |
| US-20240101533-A1 | METHODS AND INTERMEDIATES FOR PREPARING THERAPEUTIC COMPOUNDS | GILEAD SCIENCES, INC. | 2024-03-28 | — | — | US | disclosed |
| CN-116854630-A | Methods and intermediates for preparing therapeutic compounds useful in the treatment of retroviral infections | 吉利德科学公司 | 2023-10-10 | — | — | CN | disclosed |
| EP-4253366-A2 | METHODS AND INTERMEDIATES FOR PREPARING A THERAPEUTIC COMPOUND USEFUL IN THE TREATMENT OF RETROVIRIDAE VIRAL INFECTION | Gilead Sciences, Inc. (US) | 2023-10-04 | — | — | EP | disclosed |
| US-11760746-B2 | Methods and intermediates for preparing therapeutic compounds | GILEAD SCIENCES, INC. (US) | 2023-09-19 | — | — | US | disclosed |
| CN-112055712-B | Methods and intermediates for preparing therapeutic compounds useful in the treatment of retroviral infections | 吉利德科学公司 | 2023-07-14 | — | — | CN | disclosed |
| EP-3752496-B1 | METHODS AND INTERMEDIATES FOR PREPARING A THERAPEUTIC COMPOUND USEFUL IN THE TREATMENT OF RETROVIRIDAE VIRAL INFECTION | GILEAD SCIENCES INC (US) | 2023-07-05 | — | — | EP | disclosed |
| US-20220009904-A1 | METHODS AND INTERMEDIATES FOR PREPARING THERAPEUTIC COMPOUNDS | GILEAD SCIENCES, INC. | 2022-01-13 | — | — | US | disclosed |
| US-11117886-B2 | Methods and intermediates for preparing therapeutic compounds | GILEAD SCIENCES, INC. (US) | 2021-09-14 | — | — | US | disclosed |
| US-4772715-A | BLUE LIGHT ABSORBERS, PHOTOGRAPHY | EASTMAN KODAK COMPANY (US) | 1988-09-20 | — | — | US | disclosed |
| US-4677202-A | Quaternized 2,1,4-benzoxatellurazinium and 2,1,4-naphthoxatellurazinium salt derivitives | EASTMAN KODAK COMPANY (US) | 1987-06-30 | — | — | US | disclosed |
| US-4661438-A | Quaternized tellurium salt fog inhibiting agents for silver halide photography | EASTMAN KODAK COMPANY (US) | 1987-04-28 | — | — | US | disclosed |
| EP-0201201-A2 | Amido substituted divalent chalcogenide fog inhibiting agents for silver halide photography | EASTMAN KODAK COMPANY (a New Jersey corporation) (US) | 1986-11-12 | — | — | EP | disclosed |
| EP-0198634-A2 | Quaternized tellurium salt fog inhibiting agents for silver halide photography | EASTMAN KODAK COMPANY (a New Jersey corporation) (US) | 1986-10-22 | — | — | EP | disclosed |
| EP-0192466-A2 | Novel chalcogen heterocycles, processes for their preparation, and articles containing such heterocycles | EASTMAN KODAK COMPANY (a New Jersey corporation) (US) | 1986-08-27 | — | — | EP | disclosed |
| US-4607000-A | Amido substituted divalent chalcogenide fog inhibiting agents for silver halide photography | EASTMAN KODAK COMPANY (US) | 1986-08-19 | — | — | US | disclosed |
| US-4576905-A | Photographically useful chalcogenazoles, chalcogenazolines, and chalcogenazolinium and chalcogenazolium salts | EASTMAN KODAK COMPANY (US) | 1986-03-18 | — | — | US | disclosed |
| EP-0138362-A2 | Photographic materials containing chalcogenazoles, chalcogenazolines and chalcogenazolinium and chalcogenazolium salts | EASTMAN KODAK COMPANY (a New Jersey corporation) (US) | 1985-04-24 | — | — | EP | disclosed |
| EP-0136847-A2 | Photographically useful chalcogenazolylidene and chalcogenazolium dyes and methods for their preparation | EASTMAN KODAK COMPANY (a New Jersey corporation) (US) | 1985-04-10 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12122765-B2 | Methods and intermediates for preparing therapeutic compounds | CYP11A1, CYP11B1, CYP11B2 | GAA 273/4885MGAM 2133/4885SI 52/4885 |
| US-20220009904-A1 | METHODS AND INTERMEDIATES FOR PREPARING THERAPEUTIC COMPOUNDS | CYP11A1, CYP11B1, CYP11B2 | GAA 275/4885MGAM 2091/4885SI 52/4885 |
| US-11117886-B2 | Methods and intermediates for preparing therapeutic compounds | CYP11A1, CYP11B1, CYP11B2 | GAA 273/4885MGAM 2133/4885SI 52/4885 |
| US-20240101533-A1 | METHODS AND INTERMEDIATES FOR PREPARING THERAPEUTIC COMPOUNDS | CYP11A1, CYP11B1, CYP11B2 | GAA 273/4885MGAM 2133/4885SI 52/4885 |
| US-20250100999-A1 | METHODS AND INTERMEDIATES FOR PREPARING THERAPEUTIC COMPOUNDS | CYP11A1, CYP11B1, CYP11B2 | GAA 273/4885MGAM 2133/4885SI 52/4885 |
| US-11760746-B2 | Methods and intermediates for preparing therapeutic compounds | CYP11A1, CYP11B1, CYP11B2 | GAA 275/4885MGAM 2091/4885SI 52/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.